Literature DB >> 15987232

Role of antimicrobial agents in the management of exacerbations of COPD.

Sat Sharma1, Nicholas Anthonisen.   

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a common occurrence and characterize the natural history of the disease. Over the past decade, new knowledge has substantially enhanced our understanding of the pathogenesis, outcome and natural history of AECOPD. The exacerbations not only greatly reduce the quality of life of these patients, but also result in hospitalization, respiratory failure, and death. The exacerbations are the major cost drivers in consumption of healthcare resources by COPD patients. Although bacterial infections are the most common etiologic agents, the role of viruses in COPD exacerbations is being increasingly recognized. The efficacy of antimicrobial therapy in acute exacerbations has established a causative role for bacterial infections. Recent molecular typing of sputum isolates further supports the role of bacteria in AECOPD. Isolation of a new strain of Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae was associated with a considerable risk of an exacerbation. Lower airway bacterial colonization in stable patients with COPD instigates airway inflammation, which leads to a protracted self-perpetuating vicious circle of progressive lung damage and disease progression. A significant proportion of patients treated for COPD exacerbation demonstrate incomplete recovery, and frequent exacerbations contribute to decline in lung function. The predictors of poor outcome include advanced age, significant impairment of lung function, poor performance status, comorbid conditions and history of previous frequent exacerbations requiring antibacterials or systemic corticosteroids. These high-risk patients, who are likely to harbor organisms resistant to commonly used antimicrobials, should be identified and treated with antimicrobials with a low potential for failure. An aggressive management approach in complicated exacerbations may reduce costs by reducing healthcare utilization and hospitalization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15987232      PMCID: PMC7100764          DOI: 10.2165/00151829-200504030-00001

Source DB:  PubMed          Journal:  Treat Respir Med        ISSN: 1176-3450


  115 in total

Review 1.  Respiratory tract infections: when is antibiotic therapy indicated?

Authors:  H Lode
Journal:  Clin Ther       Date:  1991 Jan-Feb       Impact factor: 3.393

2.  A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.

Authors:  I M Hoepelman; M J Möllers; M H van Schie; A P Greefhorst; N J Schlösser; E J Sinninghe Damsté; C N van de Moosdijk; W H Dalinghaus; M E Eland; S J Mol; M Rozenberg-Arska
Journal:  Int J Antimicrob Agents       Date:  1997-01       Impact factor: 5.283

Review 3.  Lung infections. 1. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection.

Authors:  R A Stockley
Journal:  Thorax       Date:  1998-01       Impact factor: 9.139

4.  Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis.

Authors:  Guy W Amsden; Ian M Baird; Stuart Simon; Glenda Treadway
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

5.  Assessment of airway neutrophils by sputum colour: correlation with airways inflammation.

Authors:  R A Stockley; D Bayley; S L Hill; A T Hill; S Crooks; E J Campbell
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

Review 6.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 7.  A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

Authors:  J M Blondeau
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

8.  Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands.

Authors:  M P Rutten-van Mölken; M J Postma; M A Joore; M L Van Genugten; R Leidl; J C Jager
Journal:  Respir Med       Date:  1999-11       Impact factor: 3.415

9.  Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.

Authors:  R Kessler; M Faller; G Fourgaut; B Mennecier; E Weitzenblum
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

10.  Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study.

Authors:  G Rohde; A Wiethege; I Borg; M Kauth; T T Bauer; A Gillissen; A Bufe; G Schultze-Werninghaus
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

View more
  2 in total

1.  Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis.

Authors:  Hai-Lin Zhang; Min Tan; Ai-Min Qiu; Zhang Tao; Chang-Hui Wang
Journal:  BMC Pulm Med       Date:  2017-12-12       Impact factor: 3.317

2.  Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients.

Authors:  Theerasuk Kawamatawong; Jitsupa Onnipa; Thitiporn Suwatanapongched
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-03-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.